AI Tokens
Stock Analysis on Net

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

UnitedHealth Group Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Medical costs payable 39,352 38,930 39,659 39,337 40,181 38,427 37,136 34,224 33,951 32,547 34,032 32,395 32,792 31,947 31,809 29,056 29,064 28,978 28,676 24,483 25,918 25,131 24,833
Accounts payable and accrued liabilities 39,560 39,741 38,631 38,032 36,033 34,330 33,566 34,337 33,080 30,886 30,738 31,958 31,164 29,516 29,856 27,715 27,232 25,145 25,058 24,643 24,292 23,013 22,997
Short-term borrowings and current maturities of long-term debt 5,617 3,827 6,477 6,069 7,737 5,698 9,986 4,545 3,909 11,371 9,787 4,274 5,290 6,321 9,931 3,110 3,229 5,592 6,697 3,620 3,620 3,868 8,838
Unearned revenues 3,397 2,986 3,419 3,413 3,366 3,032 3,296 3,317 3,320 2,572 3,206 3,355 15,311 14,852 14,487 3,075 12,847 2,212 2,675 2,571 2,556 2,365 2,612
Other current liabilities 27,909 26,336 25,938 28,046 28,209 29,294 29,487 27,346 27,305 27,294 26,668 27,072 29,622 30,345 30,399 26,281 28,563 26,771 25,064 22,975 23,189 22,180 21,361
Current liabilities 115,835 111,820 114,124 114,897 115,526 110,781 113,471 103,769 101,565 104,670 104,431 99,054 114,179 112,981 116,482 89,237 100,935 88,698 88,170 78,292 79,575 76,557 80,641
Long-term debt, less current maturities 68,714 69,501 71,440 72,320 72,399 73,495 71,285 72,359 74,101 63,727 63,850 58,263 58,079 59,268 60,657 54,513 45,438 45,799 40,796 42,383 43,345 44,348 37,420
Deferred income taxes 2,528 2,722 2,864 2,421 3,162 3,804 3,902 3,620 4,014 3,631 4,167 3,021 2,210 2,498 2,834 2,769 1,659 2,581 2,954 3,265 3,649 3,641 3,602
Other liabilities 20,160 19,735 18,897 18,245 18,369 15,709 15,963 15,939 15,174 14,794 14,844 14,463 13,615 13,261 13,084 12,839 12,111 11,967 11,671 11,787 11,844 12,425 12,926
Noncurrent liabilities 91,402 91,958 93,201 92,986 93,930 93,008 91,150 91,918 93,289 82,152 82,861 75,747 73,904 75,027 76,575 70,121 59,208 60,347 55,421 57,435 58,838 60,414 53,948
Total liabilities 207,237 203,778 207,325 207,883 209,456 203,789 204,621 195,687 194,854 186,822 187,292 174,801 188,083 188,008 193,057 159,358 160,143 149,045 143,591 135,727 138,413 136,971 134,589
Redeemable noncontrolling interests 1,416 1,436 1,424 1,608 4,244 4,315 4,358 4,323 4,574 4,558 4,548 4,498 4,416 4,788 4,801 4,897 4,857 4,922 1,519 1,434 1,373 1,299 1,269
Preferred stock, $0.001 par value; no shares issued or outstanding — — — — — — — — — — — — — — — — — — — — — — —
Common stock, $0.01 par value 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 10 10 10 10 10 10 10
Additional paid-in capital — — 556 559 394 — — — 461 373 — — — — — — — — — — — — —
Retained earnings 102,021 100,957 99,878 95,603 97,595 97,250 97,934 96,036 96,518 92,400 90,118 95,774 93,173 89,994 88,852 86,156 83,722 80,540 78,782 77,134 75,124 73,090 71,220
Accumulated other comprehensive loss (3,934) (2,519) (2,562) (2,061) (2,211) (2,535) (2,905) (3,387) (2,453) (3,423) (3,439) (7,027) (8,688) (7,650) (7,549) (8,393) (9,086) (7,730) (6,026) (5,384) (4,856) (4,086) (4,826)
Shareholders’ equity attributable to UnitedHealth Group 98,096 98,447 97,881 94,110 95,787 94,724 95,038 92,658 94,535 89,359 86,688 88,756 84,494 82,353 81,312 77,772 74,646 72,820 72,766 71,760 70,278 69,014 66,404
Nonredeemable noncontrolling interests 6,033 6,066 6,014 5,980 5,782 5,745 5,773 5,610 5,346 5,317 5,682 5,665 5,070 5,015 4,509 3,678 3,418 3,385 3,362 3,285 2,981 3,008 2,909
Total equity 104,129 104,513 103,895 100,090 101,569 100,469 100,811 98,268 99,881 94,676 92,370 94,421 89,564 87,368 85,821 81,450 78,064 76,205 76,128 75,045 73,259 72,022 69,313
Total liabilities, redeemable noncontrolling interests and equity 312,782 309,727 312,644 309,581 315,269 308,573 309,790 298,278 299,309 286,056 284,210 273,720 282,063 280,164 283,679 245,705 243,064 230,172 221,238 212,206 213,045 210,292 205,171

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The balance sheet reflects a period of significant expansion in both total liabilities and total equity from March 2021 through September 2026. Total liabilities, redeemable noncontrolling interests, and equity grew from 205.17 billion USD to 312.78 billion USD, indicating a substantial increase in the overall scale of operations and financial commitments.

Current Liabilities Trends
Current liabilities exhibited a general upward trajectory, increasing from 80.64 billion USD in March 2021 to 115.84 billion USD by September 2026. A primary driver of this growth was the medical costs payable, which rose from 24.83 billion USD to 39.35 billion USD. Accounts payable and accrued liabilities followed a similar pattern, increasing from 22.99 billion USD to 39.56 billion USD. Notably, short-term borrowings demonstrated a recurring seasonal volatility, typically peaking in the first quarter of each year before declining, suggesting a systematic approach to short-term liquidity management.
Noncurrent Liabilities and Debt Profile
Noncurrent liabilities grew from 53.95 billion USD in March 2021 to 91.40 billion USD in September 2026. This increase is largely attributable to long-term debt, which expanded from 37.42 billion USD to 68.71 billion USD over the period. While long-term debt peaked at 74.10 billion USD in September 2024, a slight downward trend is observed in the final year of the analysis, suggesting a shift toward debt stabilization or repayment.
Equity and Retained Earnings
Total equity grew steadily from 69.31 billion USD in March 2021 to 104.13 billion USD in September 2026. This growth was primarily fueled by a consistent increase in retained earnings, which rose from 71.22 billion USD to 102.02 billion USD, reflecting strong internal capital generation. Accumulated other comprehensive loss showed significant fluctuation, reaching a low of -9.09 billion USD in September 2022 before recovering to -3.93 billion USD by September 2026.
Unearned Revenue Anomalies
Unearned revenues displayed irregular patterns, with significant spikes observed between September 2022 and September 2023, where values rose from 2.57 billion USD to a peak of 15.31 billion USD before reverting to levels around 3.40 billion USD. These fluctuations suggest periodic shifts in the timing of revenue recognition or the nature of contract obligations during that specific window.

The relationship between total liabilities and total equity remained relatively stable. Total liabilities increased from 134.59 billion USD to 207.24 billion USD, while total equity rose from 69.31 billion USD to 104.13 billion USD. The consistent growth in both components suggests that the expansion of the balance sheet was financed through a balanced combination of increased leverage and retained earnings.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?